Related Experiment Videos

Clinical recognition of melanoma and its precursors

R G Langley¹, A J Sober

¹Department of Dermatology, Harvard Medical School, Boston, Massachusetts, USA.

Hematology/Oncology Clinics of North America

|October 6, 1998

Abstract:

This article reviews the essential clinical features of cutaneous melanoma, as well as those of the more common benign pigmented lesions that need to be distinguished on clinical examination.

Related Concept Videos

Articles linked to this work by shared authors, journal, and citation graph.

Targeted therapies for psoriasis and atopic dermatitis in the context of malignancy: SPIN-FRT recommendations.

Journal of the European Academy of Dermatology and Venereology : JEADV·2026

Treatment of psoriasis with biologic and non-biologic targeted therapies in patients with latent tuberculosis infection or at risk for tuberculosis disease progression: Recommendations from a SPIN-FRT expert consensus.

Journal of the European Academy of Dermatology and Venereology : JEADV·2024

Super-response to guselkumab treatment in patients with moderate-to-severe psoriasis: age, body weight, baseline Psoriasis Area and Severity Index, and baseline Investigator's Global Assessment scores predict complete skin clearance.

Journal of the European Academy of Dermatology and Venereology : JEADV·2022

Long-term safety of risankizumab from 17 clinical trials in patients with moderate-to-severe plaque psoriasis.

The British journal of dermatology·2021

Five-year efficacy and safety of tildrakizumab in patients with moderate-to-severe psoriasis who respond at week 28: pooled analyses of two randomized phase III clinical trials (reSURFACE 1 and reSURFACE 2).

The British journal of dermatology·2021

A head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 24-week efficacy and safety results from a randomized, double-blinded trial.

The British journal of dermatology·2020

See all related articles